Cardiac arrythmias are common in patients undergoing maintenance hemodialysis. In this issue, Charytan et al. showed that in patients with hyperkalemia (serum potassium concentration 5.10–6.50 mmol/l [5.1–6.5 mEq/l]) on hemodialysis, a dialysate concentration of 3 mEq/l combined with sodium zirconium cyclosilicate on dialysis-free days is associated with a lower frequency of atrial fibrillation compared with a dialysate concentration of 2 mEq/l over 8 weeks. Despite the obvious limitations such as small sample size, short treatment period, and lack of information on longer-term impact on important patient outcomes such as sudden death, this well-conceived pilot study provided impetus for larger prospective trials to test whether this personalized approach reduces major cardiovascular events and mortality.

中文翻译：

---

通过个性化透析液浓度来避免心律失常：透析患者精准医疗案例


心律失常常见于接受维持性血液透析的患者。在本期中，Charytan 等 人表明，在接受血液透析的高钾血症患者（血清钾浓度 5.10-6.50 mmol/l [5.1-6.5 mEq/l]）中，与透析液浓度为 2 mEq/l 相比，在无透析日，3 mmol/l 的透析液浓度与环硅酸锆钠的发生率较低相关，持续 8 周。尽管存在明显的局限性，例如样本量小、治疗时间短以及缺乏对重要患者结果（如猝死）的长期影响的信息，但这项构思周密的试点研究为更大规模的前瞻性试验提供了动力，以测试这种个性化方法是否能降低主要心血管事件和死亡率。